The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does 10-day treatment with decitabine + venetoclax improve response in AML and high-risk MDS?

Jun 8, 2020

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak to Marina Konopleva, MD Anderson Cancer Center, Houston, US. We asked: Does 10-day treatment with decitabine + venetoclax improve response in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome?

In this video, Marina Konopleva describes the results of an investigator-initiated trial in elderly patients (over the age of 65) with newly diagnosed or relapsed/refractory AML. She describes the low early mortality rates in the two cohort groups, and very high response rates for the newly diagnosed-AML cohort, but notes that a longer follow-up and more patients are required to fully support the findings.

Does 10-day treatment with decitabine + venetoclax improve response in AML and high-risk MDS?